K. Blake

发表

The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision 1, 2012, Revision 2, 2013, Revision 3, 2014)).

A. Fourrier-Réglat, J. Hallas, S. Evans, 2012 .

Registries in European post‐marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013

M. D. De Bruin, J. Slattery, J. Bouvy, 2017, Pharmacoepidemiology and drug safety.

Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance

K. Blake, P. Arlett, Q. Yue, 2016, Pharmacoepidemiology and drug safety.

Commentary on the EMA Reflection Paper on the use of extrapolation in the development of medicines for paediatrics.

Robert Hemmings, Efthymios Manolis, Gérard Pons, 2019, British journal of clinical pharmacology.

Comparison Between Paediatric and Adult Suspected Adverse Drug Reactions Reported to the European Medicines Agency: Implications for Pharmacovigilance

F. Domergue, A. Saint‐Raymond, K. Blake, 2014, Pediatric Drugs.

The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance: application to diabetes and vascular disease:

C. Smeraldi, K. Blake, X. Kurz, 2011 .

Physiologically based pharmacokinetic modeling in regulatory decision‐making at the European Medicines Agency

E Luzon, K Blake, S Cole, 2017, Clinical pharmacology and therapeutics.

European Medicines Agency review of post‐authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance

I. Persson, K. Blake, P. Arlett, 2011, Pharmacoepidemiology and drug safety.

Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspective

Flora Musuamba Tshinanu, E. Manolis, A. Lindahl, 2023, CPT: pharmacometrics & systems pharmacology.

Enhanced Paediatric Pharmacovigilance at the European Medicines Agency: A Novel Query Applied to Adverse Drug Reaction Reports

J. Slattery, F. Domergue, A. Saint‐Raymond, 2016, Pediatric Drugs.

Increasing scientific standards, independence and transparency in post‐authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance

K. Blake, X. Kurz, P. Arlett, 2012, Pharmacoepidemiology and drug safety.

Drug‐Induced PML: A Global Agenda for a Global Challenge

G. D. Dal Pan, B. Keller-Stanislawski, K. Blake, 2012, Clinical pharmacology and therapeutics.

A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children

K. Hedenmalm, D. Morales, M. Macía, 2019, Pharmacoepidemiology and drug safety.

Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee

G. Rasi, J. Dogné, J. Raine, 2014, Nature Reviews Drug Discovery.

The European Medicines Agency's use of prioritised independent research for best evidence in regulatory action on diclofenac

S. Sarac, D. Stenver, K. Blake, 2014, Pharmacoepidemiology and drug safety.